Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
- 31 May 2013
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 14 (6), 472-480
- https://doi.org/10.1016/s1470-2045(13)70095-0
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastomaOncogene, 2012
- Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six DesignJournal of Clinical Oncology, 2008
- Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphomaMolecular Cancer Therapeutics, 2007
- Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK–positive anaplastic large-cell lymphomaBlood, 2007
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- Tissue Collection for Correlative Studies in Childhood Cancer Clinical Trials: Ethical Considerations and Special ImperativesJournal of Clinical Oncology, 2004
- Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90Blood, 2001
- Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors.1999
- A new 123I-MIBG whole body scan scoring method—Application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastomaEuropean Journal of Cancer, 1995
- Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's LymphomaScience, 1994